Encochleated amphotericin B - Matinas BioPharma

Drug Profile

Encochleated amphotericin B - Matinas BioPharma

Alternative Names: CAmB; MAT 2203

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator Aquarius Biotechnologies
  • Developer Aquarius Biotechnologies; Matinas BioPharma
  • Class Antifungals; Antiprotozoals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Aspergillosis; Candidiasis; Mycoses
  • New Molecular Entity No

Highest Development Phases

  • Phase II Candidiasis; Mycoses; Vulvovaginal candidiasis
  • Preclinical Aspergillosis; Cryptococcosis; Visceral leishmaniasis

Most Recent Events

  • 06 Mar 2017 The Institutional Review Board of the National Institute of Allergy and Infectious Diseases (NIAID) approves IND application for Phase IIa extension trial in Candidiasis
  • 06 Mar 2017 Matinas BioPharma plans a phase IIa extension trial for Candidiasis
  • 06 Jan 2017 Matinas BioPharma plans a pivotal phase III trial for encochleated amphotericin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top